Incyte said on Monday its experimental combo therapy helped patients with a type of blood cancer live longer without their ...

YD BioMed expects to advance two lead ophthalmology programs utilizing its LSC Exosome platform, each supported by targeted regulatory and clinical milestones, which the timing of these milestones ...

Breakthrough Therapy Designation is intended to expedite the development and review of medicines that are intended to treat a serious or life-threatening condition and have shown preliminary clinical ...

M+ cash runway to 2029, bitopertin FDA NDA/accelerated approval catalyst, and DISC-0974 myelofibrosis data—read now.

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

A study published earlier this year in the Journal of Neuro-Oncology indicates that sonodynamic therapy (SDT) safely destroys GBM cells while preserving healthy brain tissue. Using a noninvasive ...

The FDA has accepted a biologics license application from Inovio for a potential treatment for adults with recurrent respiratory papillomatosis. Although the application was filed under the ...

The global cell therapy market is valued at $5.5 billion in 2025 and is projected to reach $12.2 billion by 2030, reflecting strong investment in manufacturing scale, allogeneic platforms, and ...

William Blair highlighted that the key difference between this meeting and the company's prior meetings with the FDA is that Nicole Verdun was not present. Vinay Prasad was also not in the meeting.

Lexeo Therapeutics Inc. feels like it’s in a faster lane to a BLA for its Friedreich ataxia cardiomyopathy gene therapy after talking with the U.S. FDA. The agency told Lexeo that LX-2006 could be on ...

Sidney – Sidney Health Center is proud to recognize Amanda Brown, Mental and Behavioral Health Therapist, who has completed training in Accelerated Resolution Therapy (ART). Amanda has been serving ...